Results 261 to 270 of about 37,162 (308)

Second-generation antipsychotics for obsessive compulsive disorder

Cochrane Database of Systematic Reviews, 2010
Obsessive compulsive disorder (OCD) is a psychiatric disorder which has been shown to affect 2 to 3.5% of people during their lifetimes. Inadequate response occurs in 40% to 60% of people that are prescribed first line pharmaceutical treatments (selective serotonin reuptake inhibitors (SSRIs)).
Katja, Komossa, Anna M, Depping, Magdalena, Meyer, Werner, Kissling, Stefan, Leucht   +4 more
openaire   +2 more sources

Neuroprotective effects of the second generation antipsychotics

Schizophrenia Research, 2019
In contrast to over 30 studies reporting neurotoxicity associated with the first-generation antipsychotics (FGAs), several published studies have reported multiple neuroprotective effects associated with the second generation antipsychotics (SGAs).
Alexander T, Chen, Henry A, Nasrallah
openaire   +2 more sources

Age-Dependent Metabolic Effects of Second-Generation Antipsychotics in Second-Generation Antipsychotic-Naïve French Canadian Patients

Journal of Child and Adolescent Psychopharmacology, 2010
Patients receiving second-generation antipsychotics (SGAs) may experience secondary metabolic effects such as weight gain, as well as changes in lipid and glucose metabolism. These effects are well documented in adults; however, fewer studies are available concerning their occurrence and their evolution in children and adolescents.The aim of this study
Geneviève, Roy, Alain, Bedard, Paul-André, Desmarais, France, Jourdain, Sylvie, Allen, Danielle, Michaud, Leila, Ben Amor   +6 more
openaire   +2 more sources

Antipsychotic and antidepressive effects of second generation antipsychotics

European Archives of Psychiatry and Clinical Neuroscience, 2005
Second generation antipsychotics display antidepressive effects in schizophrenic patients that are more pronounced than those of traditional neuroleptics and that go beyond antidepressive effects secondary to the reduction of positive symptoms.
openaire   +2 more sources

Second generation antipsychotics for schizophrenia.

The Canadian journal of clinical pharmacology = Journal canadien de pharmacologie clinique, 2000
To provide a narrative review based on clinically relevant evidence specific to the issues surrounding the use of the second generation antipsychotics in schizophrenia.MEDLINE and Cochrane Library searches were performed to identify literature pertinent to the available and anticipated novel antipsychotics in North America.
M S, Feltus, D M, Gardner
openaire   +1 more source

Recent Second-Generation Antipsychotics

Psychopharm Review, 2012
Philip G. Janicak, Jeffrey Rado
openaire   +2 more sources

From first to second generation antipsychotics

2000
As late as 1993, 85% of psychotic inpatients at a major university psychiatric referral centre in the United States were found to be receiving antipsychotic drugs that had been available for some three decades or more, most commonly perphenazine and haloperidol, with an additional 2% receiving loxapine and 13% receiving clozapine [1].
John L. Waddington, John F. Quinn
openaire   +1 more source

Second generation antipsychotics--aripiprazole revisited.

The Medical letter on drugs and therapeutics, 2005
Six second-generation antipsychotics are marketed in the US. Is aripiprazole as effective as the others and better tolerated?
openaire   +1 more source

Integrative oncology: Addressing the global challenges of cancer prevention and treatment

Ca-A Cancer Journal for Clinicians, 2022
Jun J Mao,, Msce, Lorenzo Cohen, Karen M Mustian   +2 more
exaly  

[Paliperidone--a novel second-generation antipsychotic].

Ugeskrift for laeger, 2008
Paliperidone Depot (PAL ER) is a new second-generation antipsychotic with pharmacodynamics resembling those of risperidone. PAL ER is slowly and smoothly released in 24 hours. Its half-life is about 24 hours. PAL is primarily eliminated unchanged in urine.
Kamilla, Maknyte, Henrik K F, Lublin
openaire   +1 more source